☆ 4.7 Meeting Abstract

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

BLOOD (2020)

Get Full Text
Add to Collection

Journal

BLOOD
Volume 136, Issue -, Pages -

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2020-137451

Keywords

-

Categories

Hematology

Funding

  1. ADC Therapeutics SA

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.